|
TOR1AIP1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
6.80519973705884E-10 |
| Normal-vs-Stage3 |
1.13242748511766E-14 |
| Normal-vs-Stage4 |
3.97509802851914E-11 |
| Stage1-vs-Stage2 |
7.435000E-01 |
| Stage1-vs-Stage3 |
6.176800E-01 |
| Stage1-vs-Stage4 |
6.070000E-01 |
| Stage2-vs-Stage3 |
9.737000E-01 |
| Stage2-vs-Stage4 |
8.958400E-01 |
| Stage3-vs-Stage4 |
9.011600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
5.92480000000117E-05 |
| Normal-vs-Asian |
3.32129990177066E-10 |
| Caucasian-vs-AfricanAmerican |
1.236200E-01 |
| Caucasian-vs-Asian |
7.762000E-01 |
| AfricanAmerican-vs-Asian |
2.296200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
4.838400E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62525548574877E-12 |
| Normal-vs-Age(41-60Yrs) |
3.33066907387547E-16 |
| Normal-vs-Age(61-80Yrs) |
1.65722990885797E-12 |
| Normal-vs-Age(81-100Yrs) |
2.754000E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.437400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.412600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.398400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.796200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.587800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.765600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.278500E-02 |
| Classical-VS-Follicular |
2.006100E-02 |
| Classical-VS-Other |
4.830400E-02 |
| Classical-VS-Normal |
9.92019799639365E-11 |
| Tall-VS-Follicular |
9.926400E-01 |
| Tall-VS-Other |
1.749400E-01 |
| Tall-VS-Normal |
2.0575985359983E-11 |
| Follicular-VS-Other |
2.928600E-01 |
| Follicular-VS-Normal |
1.70075065142328E-12 |
| Other-VS-Normal |
2.41609999999115E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
3.95905530581331E-13 |
| N0-vs-N1 |
2.598000E-01 |
|
|
